[1]
|
S. H. Swerdlow, E. Campo, N. L. Harris, et al., “Acute Leukemias of Ambiguous Lineage,” In: S. H. Swerdlow, E. Campo, N. L. Harris, et al., Eds., World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 2008, pp. 150-155.
|
[2]
|
Y. Wang, M. Gu, Y. Mi, L. Qiu, S. Bian and J. Wang, “Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia with Philadelphia Chromosome Positive and/or Bcr-Abl Positive in Adult,” International Journal of Hematology, Vol. 94, No. 5, 2011, pp. 552-555. doi:10.1007/s12185-011-0953-1
|
[3]
|
P. Tosi, G. Barosi, C. Lazzaro, V. Liso, M. Marchetti, E. Morra, A. Pession, G. Rosti, A. Santoro, P. L. Zinzani and S. Tura, “Consensus Conference on the Management of Tumor Lysis Syndrome,” Hae-matologica, Vol. 93, No. 12, 2008, pp. 1877-1885. doi:10.3324/haematol.13290
|
[4]
|
N. Zojer and H. Ludwig, “Hematological Emergencies,” Annals of Oncology, Vol. 18, No. Supplement 1, 2007, pp. i45-i48. doi:10.1093/annonc/mdl450
|
[5]
|
H. Wada, T. Nagano, M. Tomeoku, M. Kuto, Y. Karitani, K. Deguchi and S. Shirakawa, “Coagulant and Fibrinolytic Activities in the Leukemic Cell Lysates,” Thrombosis Research, Vol. 30, No. 4, 1983, pp. 315-322.
doi:10.1016/0049-3848(83)90223-2
|
[6]
|
M. Levi and H. T. Cate, “Disseminated Intravascular Coagulation,” The New England Journal of Medicine, Vol. 341, No. 8, 1999, pp. 586-592.
doi:10.1056/NEJM199908193410807
|
[7]
|
T. Iba, E. Nakarai, T. Takayama, K. Nakajima, T. Sasaoka and Y. Ohno, “Combination Effect of Antithrombin and Recombinant Human Soluble Thrombomodulin in a Lipopolysaccharide Induced Rat Sepsis Model,” Critical Care, Vol. 13, No. 6, 2009, p. R203. doi:10.1186/cc8210
|
[8]
|
K. Yamakawa, S. Fujimi, T. Mohri, H. Matsuda, Y. Nakamori, T. Hirose, O. Tasaki, H. Ogura, Y. Kuwagata, T. Hamasaki and T. Shimazu, “Treatment Effects of Recombinant Human Soluble Thrombomodulin in Patients with Severe Sepsis: A Historical Control Study,” Critical Care, Vol. 15, No. 3, 2011, p. R123. doi:10.1186/cc10228
|
[9]
|
S. Moll, C. Lindley, S. Pescatore, D. Morrison, K. Tsuruta, M. Mohri, M. Serada, M. Sata, H. Shimizu, K. Yamada and G. C. White, “Phase I Study of a Novel Recombinant Human Soluble Thrombomodulin, ART-123,” Journal of Thrombosis and Haemostasis, Vol. 2, No. 10, 2004, pp. 1745-1751. doi:10.1111/j.1538-7836.2004.00927.x
|
[10]
|
H. Saito, S. Maruyama, S. Shimazaki, Y. Yamamoto, N. Akikawa, R. Ohno, A. Hirayama, T. Matsuda, H. Asakura, M. Nakashima and N. Aoki, “Efficacy and Safety of Recombinant Human Soluble Thrombomodulin (ART-123) in Disseminated Intravascular Coagulation: Results of a Phase III, Randomized, Double-Blind Clinical Trial,” Journal of Thrombosis and Haemostasis, Vol. 5, No. 1, 2007, pp. 31-41. doi:10.1111/j.1538-7836.2006.02267.x
|
[11]
|
F. B. Taylor Jr, C. H. Toh, W. K. Hoots, H. Wada and M. Levi, “Towards Definition, Clinical and Laboratory Criteria and a Scoring System for Disseminated Intravascular Coagulation,” Thrombosis and Haemostasis, Vol. 86, No. 5, 2001, pp. 1327-1330.
|
[12]
|
E. Matutes, W. F. Pickl, M. Van’t Veer, et al., “Mixed-Phenotype Acute Leukemia: Clinical and Laboratory Features and Outcome in 100 Patients Defined According to the WHO 2008 Classification,” Blood, Vol. 117, No. 11, 2011, pp. 3163-3171. doi:10.1182/blood-2010-10-314682
|
[13]
|
M. C. Bene, G. Castoldi, W. Knapp, et al., “Proposals for the Immunological Classification of Acute Leukemias. European Group for the Immunological Characterization of Leukemias (EGIL),” Leukemia, Vol. 9, No. 10, 1995, pp. 1783-1786.
|
[14]
|
S. Killick, E. Matutes, R. L. Powles, et al., “Outcome of Biphenotypic Acute Leukemia,” Haematologica, Vol. 84, No. 8, 1999, pp. 699-706.
|
[15]
|
Y, Zhang, D, Wu, A. Sun, et al., “Clinical Characteristics, Biological Profile, and Outcome of Biphenotypic Acute Leukemia: A Case Series,” Acta Haematologica, Vol. 125, No. 4, 2011, pp. 210-218. doi:10.1159/000322594
|
[16]
|
I. Maruyama, “Recombinant Thrombomodulin and Activated Protein C in the Treatment of Disseminated Intravascular Coagulation,” Thrombosis and Haemostasis, Vol. 82, No. 2, 1999, pp. 718-721.
|
[17]
|
E. Ogawa, H. Yagasaki, M. Kato, et al., “Successful Treatment of Disseminated Intravascular Coagulation in a Child with Acute Myelogenous Leukaemia Using Recombinant Thrombomodulin,” British Journal of Haematology, Vol. 149, No. 6, 2010, pp. 911-912.
doi:10.1111/j.1365-2141.2010.08135.x
|
[18]
|
K. Abeyama, D. M. Stern, Y. Ito, et al., “The N-Terminal Domain of Throm-bomodulin Sequesters High-Mobility Group-B1 Protein, a Novel Anti-Inflammatory Mechanism,” The Journal of Clinical Investigation, Vol. 115, No. 5, 2005, pp. 1267-1274.
|
[19]
|
T. Ito, K. Kawahara, K. Okamoto, et al., “Proteolytic Cleavage of High Mobility Group Box 1 Protein by Thrombin-Thrombomodulin Complexes,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 28, No. 10, 2008, pp. 1825-1830.
doi:10.1161/ATVBAHA.107.150631
|